Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Pictilisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 15/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 14/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 12/20 | 1.00 |
| ▸ | PIK3R2 known ✓ | O00459 | 1/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 1.00 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pictilisib SCHEMBL14859338 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL190812 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29387739 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL190513 | 0.98 | PIK3CA (0.95) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29370279 | 0.98 | ABCC4 (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29915227 | 0.98 | ABCC4 (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL3045698 | 0.95 | ABCC4 (0.92) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL31237882 | 0.94 | PIK3CA (0.89) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL31205 | 0.94 | PIK3CA (0.88) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL190211 | 0.93 | PIK3CA (0.87) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119301125-A | Crystalline forms of AKR1C3 dependent KARS inhibitors | 诺华股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119241499-A | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| WO-2022243846-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-4076660-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022215011-A1 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| CN-115052662-A | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases | 诺华股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| CN-109311876-B | Heteroaryl estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3475285-B1 | MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | PIK3CA 3671/4885PIK3CD 4134/4885PIK3CB 4475/4885 |
| US-11242346-B2 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | MTOR, RPTOR, RICTOR | PIK3CA 20/4885PIK3CD 27/4885PIK3CB 29/4885 |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | AKR1C3, AKR1C1, AKR1C2 | PIK3CA 1766/4885PIK3CD 2697/4885PIK3CB 1915/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | PIK3CA 3348/4885PIK3CD 2708/4885PIK3CB 3112/4885 |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | PIK3CA 3671/4885PIK3CD 4134/4885PIK3CB 4475/4885 |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NPY2R, NPY5R, RXFP1 | PIK3CA 3931/4885PIK3CD 4214/4885PIK3CB 4488/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | PIK3CA 3215/4885PIK3CD 3622/4885PIK3CB 4073/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | PIK3CA 2892/4885PIK3CD 3348/4885PIK3CB 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.